Fund Evaluation Group’s Biogen BIIB Stock Holding History

Fund Evaluation Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,800	Closed	-$1.7M	–	33
2018 Q3	$1.7M	Hold	4,800	–	–	0.28%	36
2018 Q2	$1.39M	Hold	4,800	–	–	0.22%	50
2018 Q1	$1.31M	Hold	4,800	–	–	0.15%	54
2017 Q4	$1.53M	Buy	+4,800	New	+$1.54M	0.16%	52

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fund Evaluation Group's BIIB Position: Q4 2018 in Review

Fund Evaluation Group sold out of Biogen (BIIB) in Q4 2018, closing a stake of 4,800 shares — an estimated $1.7M sold.

Fund Evaluation Group first reported a position in BIIB in Q4 2017 and held it in 4 quarters. The position peaked at $1.7M in Q3 2018. 1,140 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

Fund Evaluation Group reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
Fund Evaluation Group sold 4,800 Biogen shares in Q4 2018, an estimated $1.7M.
Fund Evaluation Group first reported a position in Biogen in Q4 2017 and held it in 4 quarters.
Fund Evaluation Group's Biogen position peaked at $1.7M in Q3 2018.
1,140 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on Fund Evaluation Group's 13F filing for Q4 2018, filed 12 Feb 2019.